Imaging tumor burden in IDH mutant glioma using hyperpolarized carbon-13 alpha-ketoglutarate

Hyperpolarized Carbon-13 Alpha-ketoglutarate Metabolic Imaging in IDH Mutant Glioma

This study is testing a new MRI technique using a special substance to see how well it can show tumor size in patients with a specific type of brain cancer called IDH mutant glioma.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University of California, San Francisco (Academic / other)
• Locations: 1 site (San Francisco, California)
• Trial ID: NCT05851378 on ClinicalTrials.gov

What this trial studies

This study investigates the use of hyperpolarized carbon-13 alpha-ketoglutarate (HP 13C-aKG) to characterize tumor burden in patients with isocitrate dehydrogenase (IDH) mutant glioma. It aims to define optimal imaging parameters for HP 13C-aKG and assess the safety and feasibility of this novel magnetic resonance imaging technique. Participants will be divided into two cohorts: those with IDH mutant glioma for sequence development and those with recurrent IDH mutant glioma prior to surgical resection. The study involves one MRI scan with HP 13C-aKG administration and a follow-up call to monitor for any late adverse events.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 years old with evaluable IDH mutant glioma, either newly diagnosed or recurrent, who meet specific health criteria.

Not a fit: Patients without IDH mutations or those with contraindications for MRI examinations may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new imaging tool to better evaluate tumor burden in patients with IDH mutant glioma.

How similar studies have performed: While the use of hyperpolarized imaging is a novel approach, similar studies have shown promise in metabolic imaging techniques for tumor characterization.

Eligibility criteria

Inclusion Criteria:

1\. Participants must be \> 18 years old who have evidence of evaluable disease (with contrast enhancing lesion or non-enhancing lesion \> 1 cubic centimetre (cc))

* Cohort 1: Participants with IDH mutant glioma who may or may not have received prior treatment
* Cohort 2: Participants with recurrent IDH mutant glioma before receiving surgical resection,

All the subjects must have prior MR scans available for review to assess the location and size of residual/recurrent tumor and do not have contraindication for magnetic resonance (MR) examinations. To be included in the study all subjects must also meet the following criteria:

1. Participants must have a life expectancy \> 8 weeks.
2. Participants must have a Karnofsky performance status of \> 70.
3. Participants must have adequate renal function (creatinine \< 1.5 mg/dL). This test must be performed within 60 days prior to the HP 13C Imaging scan.
4. Participants must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the participant's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent.
5. Participants must not have New York Heart Association (NYHA) Grade II or greater congestive heart failure.
6. Participants must not have history of myocardial infarction or unstable angina within 12 months prior to study enrollment.
7. This study was designed to include women and minorities but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. Minorities will actively be recruited to participate. No exclusion to this study will be based on race.
8. Participants must sign an informed consent indicating that they are aware of the investigational nature of this study. Participants must sign an authorization for the release of their protected health information.
9. Participants may not be known to be HIV-positive. HIV testing is not required for study participation.
10. Participants must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless they are in complete remission and have been off all therapy for that disease for a minimum of 3 years.
11. Participants must not be pregnant or breast-feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of Hyperpolarized Imaging scan. Effective contraception (men and women) must be used in subjects of childbearing potential.

Exclusion Criteria:

1\. Participants are excluded from participating in this study if they are not able to comply with study procedures.

Where this trial is running

San Francisco, California

• University of California, San Francisco — San Francisco, California, United States (Recruiting)

Study contacts

• Principal investigator: Susan Chang, MD — University of California, San Francisco
• Study coordinator: Wendy Ma

Conditions Adult Gliomas, Mixed; Isocitrate Dehydrogenase Mutation